

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/162426/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Proal, Amy D., VanElzakker, Michael B., Aleman, Soo, Bach, Katie, Boribong, Brittany P., Buggert, Marcus, Cherry, Sara, Chertow, Daniel S., Davies, Helen E., Dupont, Christopher L., Deeks, Steven G., Eimer, William, Ely, E. Wesley, Fasano, Alessio, Freire, Marcelo, Geng, Linda N., Griffin, Diane E., Henrich, Timothy J., Iwasaki, Akiko, Izquierdo-Garcia, David, Locci, Michela, Mehandru, Saurabh, Painter, Mark M., Peluso, Michael J., Pretorius, Etheresia, Price, David A. , Putrino, David, Scheuermann, Richard H., Tan, Gene S., Tanzi, Rudolph E., VanBrocklin, Henry F., Yonker, Lael M. and Wherry, E. John 2023. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). *Nature Immunology* 24 , pp. 1616-1627. [10.1038/s41590-023-01601-2](https://doi.org/10.1038/s41590-023-01601-2)

Publishers page: <http://dx.doi.org/10.1038/s41590-023-01601-2>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)

2
3 Amy D. Proal¹, Michael B. VanElzakker², Soo Aleman³, Katie Bach⁴, Brittany P. Boribong⁵,
4 Marcus Buggert⁶, Sara Cherry⁷, Daniel S. Chertow⁸, Helen E. Davies⁹, Christopher L. Dupont¹⁰,
5 Steven Deeks¹¹, William Eimer¹², E. Wesley Ely¹³, Alessio Fasano¹⁴, Marcelo Freire¹⁵, Linda N.
6 Geng¹⁶, Diane Griffin¹⁷, Timothy J. Henrich¹⁸, Akiko Iwasaki¹⁹, David Izquierdo-Garcia²⁰, Michela
7 Locci²¹, Saurabh Mehandru²², Mark Painter²³, Michael J. Peluso²⁴, Ethersia Pretorius²⁵,
8 David A. Price²⁶, David Putrino²⁷, Richard H. Scheuermann²⁸, Gene S. Tan²⁹, Rudolph E. Tanzi
9 ³⁰, Henry F. VanBrocklin³¹, Lael M. Yonker³², E. John Wherry³³

- 10
- 11 1. PolyBio Research Foundation, Medford, MA, USA
- 12 2. Division of Neurotherapeutics, Massachusetts General Hospital, Harvard Medical School,
13 Boston, MA, USA, 2) PolyBio Research Foundation, Medford, MA, USA
- 14 3. Dept of Infectious Diseases and Unit of Post-Covid Huddinge, Karolinska University
15 Hospital, Sweden
- 16 4. PolyBio Research Foundation, Medford, MA, USA; Nonresident Senior Fellow, Brookings
17 Institution
- 18 5. Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA 2) Mucosal
19 Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA,
20 USA 3) Harvard Medical School, Boston, MA, USA
- 21 6. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
22 Huddinge, Sweden
- 23 7. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, UPENN
- 24 8. Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National
25 Institutes of Health, Bethesda, MD, USA 2) Laboratory of Immunoregulation, National
26 Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD,
27 USA
- 28 9. Department of Respiratory Medicine, University Hospital Llandough, Cardiff University
29 School of Medicine, University Hospital of Wales, Cardiff, UK
- 30 10. J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA, USA
- 31 11. Division of HIV, Infectious Diseases, and Global Medicine, University of California, San
32 Francisco, CA, USA
- 33 12. Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease,
34 Charlestown, MA, USA 2) Department of Neurology, Massachusetts General Hospital and
35 Harvard Medical School, Charlestown, MA, USA 3) McCance Cancer Center for Brain
36 Health, Massachusetts General Hospital, Boston, MA, USA
- 37 13. The Critical Illness, Brain Dysfunction, Survivorship (CIBS) Center at Vanderbilt University
38 Medical Center and the Veteran's Affairs Tennessee Valley Geriatric Research Education
39 Clinical Center (GRECC), Nashville, TN, USA
- 40 14. Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA 2) Mucosal
41 Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA,
42 USA 3) Harvard Medical School, Boston, MA, USA

- 1 **15.** J. Craig Venter Institute Department of Infectious Diseases, University of California San
2 Diego
- 3 **16.** Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
- 4 **17.** W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns
5 Hopkins Bloomberg School of Public Health
- 6 **18.** Division of Experimental Medicine, University of California, San Francisco, USA
- 7 **19.** Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
8 2) Center for Infection and Immunity, Yale University School of Medicine, New Haven, CT,
9 USA. 3) Howard Hughes Medical Institute, Chevy Chase, MD, USA.
- 10 **20.** Department of Radiology, Harvard Medical School, Charlestown, Massachusetts, USA 2)
11 Department of Health Sciences and Technology, Massachusetts Institute of Technology,
12 Cambridge, Massachusetts, USA
- 13 **21.** Institute for Immunology and Immune Health, and Department of Microbiology,
14 University of Pennsylvania Perelman School Medicine, Philadelphia, Pennsylvania, USA
- 15 **22.** Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
16 USA 2) Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn
17 School of Medicine at Mount Sinai, New York, NY, USA
- 18 **23.** Institute for Immunology and Immune Health, and Department of Microbiology,
19 University of Pennsylvania Perelman School Medicine, Philadelphia, Pennsylvania, USA
- 20 **24.** Division of HIV, Infectious Diseases, and Global Medicine, University of California, San
21 Francisco, CA, USA
- 22 **25.** Department of Physiological Sciences, Faculty of Science, Stellenbosch University,
23 Stellenbosch, South Africa 2) Department of Biochemistry and Systems Biology, Institute
24 of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences,
25 University of Liverpool, UK
- 26 **26.** Division of Infection and Immunity, Cardiff University School of Medicine, University
27 Hospital of Wales, Cardiff, UK. 2) Systems Immunity Research Institute, Cardiff University
28 School of Medicine, University Hospital of Wales, Cardiff, UK.
- 29 **27.** Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY
30 Department of Rehabilitation and Human Performance 2) Icahn School of Medicine at
31 Mount Sinai, New York City, NY
- 32 **28.** Department of informatics, J. Craig Venter Institute, La Jolla, CA, USA 2) Department of
33 Pathology, University of California, San Diego, CA, USA 3) La Jolla Institute for
34 Immunology, San Diego, CA, USA
- 35 **29.** J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA, USA 2) Department of
36 Infectious Diseases, University of California San Diego, La Jolla, CA, USA
- 37 **30.** Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease,
38 Charlestown, MA, USA 2) Department of Neurology, Massachusetts General Hospital and
39 Harvard Medical School, Charlestown, MA, USA 3) McCance Cancer Center for Brain
40 Health, Massachusetts General Hospital, Boston, MA, USA
- 41 **31.** Department of Radiology and Biomedical Imaging, University of California San Francisco,
42 San Francisco, CA, USA

1 32. Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA 2) Mucosal
2 Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA,
3 USA 3) Harvard Medical School, Boston, MA, USA

4 33. Institute for Immunology and Immune Health, and Department of Systems Pharmacology
5 and Translational Therapeutics, University of Pennsylvania Perelman School Medicine,
6 Philadelphia, Pennsylvania, USA

7 **Corresponding author: Amy D. Proal, aproal@polybio.org**

8 9 **Summary/abstract**

10
11 Millions of patients are suffering from Long COVID or Post-Acute Sequelae of COVID-19 (PASC).
12 Several biological factors have emerged as potential drivers of PASC pathology. Some
13 individuals with PASC may not fully clear the SARS-CoV-2 virus after acute infection. Instead,
14 replicating virus and/or viral RNA - potentially capable of being translated to produce viral
15 proteins - persist in tissue as a "reservoir." This reservoir could modulate host immune
16 responses or release viral protein into the circulation. Here, we review studies that have
17 identified SARS-CoV-2 RNA/protein or immune responses indicative of a SARS-CoV-2 reservoir
18 in PASC samples. Mechanisms by which a SARS-CoV-2 reservoir may contribute to PASC
19 pathology including coagulation, microbiome, and neuroimmune abnormalities are delineated.
20 We identify research priorities to guide the further study of a SARS-CoV-2 reservoir in PASC,
21 with the goal that clinical trials of antivirals or other therapeutics with potential to clear a SARS-
22 CoV-2 reservoir are accelerated.

23 24 **Introduction**

25
26 A significant subset of individuals infected with the SARS-CoV-2 virus develop new symptoms or
27 sequelae that do not resolve for months or years. This condition is known as Long COVID or
28 post-acute sequelae of COVID-19 (PASC) ¹. Based on the Census Bureau Household Pulse
29 Survey, the US Centers for Disease Control and Prevention estimates that ~6% of US adults
30 suffer from new symptoms lasting three or more months after contracting COVID-19². Of those,
31 80.7% state that their new symptoms limit their ability to carry out day-to-day activities; 26.2%
32 say that their activity is limited "a lot". Estimates place the total US economic cost of PASC at
33 approximately \$743 billion per year, including reduced quality of life, lost earnings, and
34 increased medical spending³.

35
36 Common PASC symptoms include fatigue, flu-like symptoms, autonomic dysfunction, trouble
37 with memory or concentration, and post-exertional malaise (PEM) ⁴. However, more than 200
38 PASC symptoms have been documented and symptom presentation can differ from patient to
39 patient ^{5 6}. In addition, many individuals with PASC report symptoms of fluctuating severity or a
40 relapsing/remitting nature⁷. PASC can occur in children, with an incidence of up to 25% of cases
41 in earlier COVID-19 waves⁸, and more recent reports suggesting that roughly 6% of children
42 infected with SARS-CoV-2 meet PASC criteria.⁹ The most severe post-COVID-19 sequelae in
43 children is multisystem inflammatory syndrome (MIS-C): a sometimes fatal SARS-CoV-2-related
44 inflammatory disorder that has been defined as part of the PASC spectrum. More than 9,300

1 children have developed MIS-C in the US alone ¹⁰. Overall, the tremendous disability and
2 economic burden of PASC on both adult and pediatric populations requires that core biological
3 drivers of the disease process be rapidly delineated.

4
5 Several biological trends are emerging as primary potential drivers of PASC pathology. One is
6 that a significant proportion of individuals with PASC may not fully clear SARS-CoV-2 after initial
7 infection. Instead, replicating virus and/or viral RNA - potentially capable of being translated to
8 produce viral proteins - may persist in PASC patient tissues in a "reservoir." SARS-CoV-2 is a
9 positive-sense single-stranded RNA virus from the *Coronaviridae* family. There is precedence for
10 the persistence of other single-stranded RNA viruses after acute illness. RNA from Ebola virus
11 (EBOV) ¹¹⁻¹³, Zika virus (ZIKV)¹⁴, enteroviruses ^{15,16}, and measles^{17 18} has been identified in tissue
12 obtained months or years after initial infection. In multiple instances these viral reservoirs have
13 been shown capable of driving chronic disease ^{19 20}. In the case of Ebola virus disease (EBV),
14 new outbreaks of disease have been sparked by individuals carrying persistent EBOV years after
15 acute illness ^{21 22}, and there are multiple reports of sexual transmission of ZIKV many months
16 after recovery from acute disease²³.

17
18 In this review, we explore evidence for SARS-CoV-2 reservoir in PASC and provide context on
19 interpretation of the findings. We delineate mechanisms by which a SARS-CoV-2 reservoir may
20 contribute to PASC pathology and identify central research priorities and methods to guide the
21 continued study of SARS-CoV-2 persistence in PASC. If used synergistically, these approaches
22 should reveal biomarkers and therapeutic candidates for PASC clinical trials including
23 immunomodulators and direct-acting and host-directed antivirals.

24 25 **SARS-CoV-2 is capable of persistence in many body sites**

26
27 Autopsy and tissue biopsy studies have identified SARS-CoV-2 RNA and protein in a wide range
28 of tissue types collected weeks or months after acute COVID-19 ^{24-26 27 28 29 30}. Most of these
29 studies were not designed to measure PASC symptoms, but nevertheless provide evidence that
30 SARS-CoV-2 is capable of persistence in numerous reservoir sites (Table 1). One autopsy study
31 identified SARS-CoV-2 RNA and protein in dozens of body tissues and brain obtained at least 31
32 days and up to 230 days after COVID-19 symptom onset ³¹. Over 50% of these cases had
33 persistent RNA in lymph nodes from the head and neck, and from the thorax, sciatic nerve,
34 ocular tissue, and in most sampled regions of the CNS including the cervical spinal cord,
35 brainstem, and olfactory nerve. In one individual who died 230 days after mild COVID-19, SARS-
36 CoV-2 RNA was identified in multiple anatomical sites, including several brain regions.
37 Subgenomic (Sg)RNA - a potential marker of recent viral replication - was identified in tissues
38 post-acute COVID-19, including in multiple tissues of a case at day 99 - indicating that viral
39 replication may occur in non-respiratory tissues for several months. Another study identified
40 SARS-CoV-2 RNA in 80% of lung tissue samples obtained from individuals up to 174 days after
41 COVID-19 onset ³².

42
43 SARS-CoV-2 RNA or protein has been identified in tissue months after initial illness despite
44 negative results via standard nasopharyngeal PCR testing and/or a lack of detection in

1 peripheral blood from the same individual^{31 33}. These observations suggest that SARS-CoV-2
2 persistence occurs largely in tissues. Indeed, most human tissue types are dense with cells
3 expressing the angiotensin 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2)
4 receptors SARS-CoV-2 uses for cell entry. A similar pattern has been documented with other
5 RNA viruses associated with chronic sequelae in a subset of survivors^{34 35 36}. Immune responses
6 against SARS-CoV-2 RNA and protein, including those indicative of persistence, can also be
7 localized to tissue and not necessarily apparent in the blood from the same individuals.³⁷

9 **SARS-CoV-2 reservoir in PASC**

11 A major gap in the field is the absence of PASC-specific autopsy data. Thus, most evidence for
12 SARS-CoV-2 reservoir in individuals with PASC comes from: 1) tissue biopsy studies; 2) studies of
13 SARS-CoV-2 proteins in plasma; and 3) studies using features of the adaptive immune response
14 to infer presence of a SARS-CoV-2 reservoir in tissues. For example, to investigate the intestinal
15 mucosa as a SARS-CoV-2 reservoir site in PASC, Zollner *et al.* performed a tissue biopsy study of
16 individuals with inflammatory bowel disease undergoing endoscopy³⁸. Despite mild acute
17 infections, 70% of subjects harbored SARS-CoV-2 RNA in intestinal mucosal tissue and 52% had
18 nucleocapsid protein in intestinal epithelium ~7 months following COVID-19. Viral RNA and
19 protein persistence were unrelated to the severity of acute COVID-19 or immunosuppressive
20 therapy, but did associate with PASC symptoms. Another study identified SARS-CoV-2 RNA and
21 nucleocapsid protein (N) in the skin, appendix, and breast tissue of two individuals who
22 exhibited PASC symptoms 163 and 426 days after acute COVID-19³⁹. SARS-CoV-2 RNA or
23 protein was also detected in olfactory mucosa samples 110-196 days after symptom onset in 3
24 patients with negative nasopharyngeal swab RT-PCR, but ongoing anosmia²⁷.

26 Multiple studies have identified SARS-CoV-2 proteins in PASC plasma, months or even > 1 year
27 after acute COVID-19. This protein is likely derived from PASC tissue reservoir sites, but "leaks"
28 into the circulation where it can be measured. In a study restricted to unvaccinated individuals,
29 Schultheiß *et al.* detected SARS-CoV-2 S1 protein in the plasma of approximately 64% of PASC
30 study participants recruited at a median of 8 months (range 1-17 months) after acute COVID-
31 19, but only in approximately 35% of convalescent controls⁴⁰. Using an optimized ultra-
32 sensitive single-molecule array (Simoa) method, Swank *et al.* identified either spike, S1, or
33 nucleocapsid (N) protein in ~65% of plasma samples collected from PASC patients several
34 months after SARS-CoV-2 infection⁴¹. Spike was detected most often: in 60% of PASC
35 participants up to 12 months post COVID-19 onset, with no spike detected in COVID-19
36 convalescent controls. Viral protein was detected at more than one timepoint in all 12 of the 37
37 PASC cases for whom the team had obtained longitudinal samples. Additional Simoa analyses in
38 another post-acute cohort⁷ including PASC and fully recovered individuals, found that 24% of all
39 post-acute participants had ≥ 1 detectable SARS-CoV-2 protein in plasma during at least one
40 timepoint up to 16 months post-COVID⁴² with most of these data obtained before subjects had
41 received any SARS-CoV-2 vaccine, a potential confounder in such analyses⁴³. The presence of
42 persistent protein was associated with more severe initial infection, with the highest
43 prevalence of protein persistence observed in participants who were consistently the most

1 symptomatic (35% of participants with ≥ 9 symptoms). Notably, a subset of convalescent
2 controls who reported full recovery (18%) also had detectable viral protein in plasma.

3
4 In addition to persisting as soluble protein in circulation, SARS-CoV-2 proteins including spike
5 have been detected in PASC plasma in extracellular vesicles (EVs). One team found higher SARS-
6 CoV-2 S1 and N protein in enriched neuron-derived and astrocyte-derived EVs in plasma from
7 PASC individuals versus convalescent controls ⁴⁴. Craddock *et al.* identified spike protein in the
8 plasma of 64% of PASC patients and 29% of convalescent controls ⁴⁵. They additionally found
9 higher total and relative quantity of EV-associated spike protein in the PASC group, and
10 implicated surface heparin sulfate proteoglycan in spike binding. SARS-CoV-2 RNA was
11 identified in 59% of PASC samples and 28% of convalescent controls, yet only PASC study
12 participants harbored both spike protein and viral RNA in the same sample. Whether the viral
13 RNA and EV-associated spike protein originate from the same tissue or cellular source and why
14 they are detected as separate entities remains unclear. Overall, EVs may facilitate the transport
15 of SARS-CoV-2 proteins from tissue reservoir sites into the circulation.

16
17 The identification of SARS-CoV-2 protein in PASC plasma up to 16 months post-COVID suggests
18 that some PASC individuals may harbor replicating virus. However, thus far, levels of protein
19 detected differ widely among studies, suggesting that the size and/or activity of any SARS-CoV-
20 2 reservoirs may vary among PASC patients. Failure to detect SARS-CoV-2 protein in the plasma
21 of some PASC patients could be interpreted to mean absence of a SARS-CoV-2 reservoir.
22 However, such a result could also indicate a reservoir in tissues or sites where viral protein may
23 be less likely to reach the circulation at the level of detection of current assays. In addition,
24 protein could be bound by antibodies, preventing recognition by some assays. Moreover, SARS-
25 CoV-2 protein might also be captured and potentially persist inside neutrophil extracellular
26 traps (NETs) or host immune cells such as macrophage and thus also fail to be detected via
27 analyses of plasma alone.

28
29 Variability in detection of different viral proteins in PASC plasma could also reflect differences in
30 SARS-CoV-2 translational activity. For example, Swank *et al.* reported multiple PASC cases in
31 which spike protein was identified in plasma of the same individual at some timepoints but not
32 others ⁴¹. These findings suggest it may be possible that SARS-CoV-2 in a reservoir could have
33 periods of inactivity and resume protein production and/or replication at other times such as
34 when immune control is altered. Such a phenomenon is in line with the fluctuating symptoms
35 reported by many PASC individuals. A study of survivors with post-Ebola syndrome suggests
36 that the activity of persistent viral RNA in reservoir sites can change over time. Adaken *et al.*
37 reported declines and subsequent rises - or a “decay–stimulation–decay” pattern - in
38 neutralizing antibody (nAb) in the plasma of EVD survivors ⁴⁶. This periodic nAb resurgence
39 likely corresponds to periods of more active replication in EBOV reservoir sites, followed by
40 periods of relative inactivity. Similar waves of recurrent immune activation consistent with
41 periodic increases in immune stimulation by viral proteins have also been documented in
42 measles ⁴⁷. Further interrogating such relationships in PASC is warranted.

43

1 Additional research is needed to better understand the role of persistent SARS-CoV-2 protein or
2 RNA in causing ongoing symptoms. For example, it will be necessary to interrogate how
3 location of infection and viral dissemination within the host, transcriptional/translational
4 activity of SARS-CoV-2 RNA, virus genomic evolution, human genomic variants, HLA haplotypes,
5 and other variables are connected to differences in host innate and adaptive responses and/or
6 predispose to persistence of viral protein or RNA. Moreover, interrogating factors underlying
7 the detection of viral protein in convalescent subjects without PASC – albeit at lower levels than
8 in PASC participants – will be of considerable interest. Such studies should help determine the
9 relationships between viral persistence, immune responses, and development of PASC in only
10 some individuals following SARS-CoV-2 infection.

11

12 **Adaptive immunity and PASC SARS-CoV-2 reservoir**

13

14 The immune response can act as a sensitive indicator of virus persistence. T cell differentiation
15 is strongly influenced by antigen exposure, even if low-level and chronic^{48 49}. T cells can detect
16 a single HLA/peptide complex and the process of antigen recognition triggers phenotypic and
17 transcriptional changes among responsive T cells^{50–52 53}. T cells also often become more
18 sensitive to other environmental signals because of their activation⁴⁹. Therefore, distinct
19 patterns of T cell differentiation can provide clues to infer the presence of a SARS-CoV-2
20 reservoir. For example, Vibholm *et al.* analyzed SARS-CoV-2-specific CD8⁺ T cell responses using
21 a dextramer stain for nine different CD8⁺ T cell epitopes⁵⁴. Individuals who harbored SARS-CoV-
22 2 pharyngeal RNA two weeks post-COVID had increased breadth and magnitude of SARS-CoV-2-
23 specific CD8⁺ T cell responses.

24

25 Multiple studies have identified SARS-CoV-2 specific T cells or altered responses to SARS-CoV-2
26 peptide pool stimulation in at least a subset of PASC participants, consistent with viral or
27 antigen persistence⁵⁵. Littlefield *et al.* quantified inflammatory markers and SARS-CoV-2-
28 specific T cells in PASC versus convalescent participants⁵⁶. The circulating frequencies of
29 functionally responsive CD4⁺ and CD8⁺ T cells, identified by measuring cytokine production in
30 response to stimulation with SARS-CoV-2 peptide pools, were 6- to 105-fold higher in
31 individuals with pulmonary PASC. These patients also displayed elevated plasma C-reactive
32 protein and IL-6 compared to controls. Similar findings were reported in a study of individuals
33 with neurological PASC, who exhibited more pronounced cellular and humoral immune
34 responses targeting the SARS-CoV-2 N protein compared to convalescent controls⁵⁷.

35

36 Other teams have identified markers of persisting immune activation and/or T cell exhaustion
37 consistent with ongoing stimulation by SARS-CoV-2 antigens and/or a skewed inflammatory
38 environment in PASC patients. For example, Yin *et al.* found that PASC patients harbored
39 significantly higher SARS-CoV-2 antibodies, and elevated frequencies of Tcm, Tfh, and Treg in
40 blood⁵⁸. Production of IL-6 by SARS-CoV-2 spike-specific CD4⁺ T cells was detected in some
41 PASC patients, suggesting a potential link to inflammatory responses. SARS-CoV-2-specific CD8⁺
42 T cells from PASC patients also more frequently expressed PD-1 and CTLA-4: markers of recent
43 T cell activation and/or exhaustion. Indeed, Klein *et al.* found that elevated frequencies of CD8⁺
44 T cells and CD4⁺ T cells from PASC patients expressed both PD-1 and Tim-3⁵⁹, consistent with

1 chronic antigen stimulation and presence of exhausted T cells (Tex). Elevated anti-spike
2 antibody responses in plasma were also identified in individuals with PASC, suggestive of
3 persistent spike protein driving elevation in the humoral responses.

4
5 Some adaptive immune responses in PASC blood are consistent with a SARS-CoV-2 reservoir in
6 mucosal tissue. In the Yin *et al.* study, CD4⁺ T cells in PASC individuals preferentially expressed
7 the CCR6, CXCR4, and CXCR5 chemokine receptors that can direct T cells to inflammatory sites,
8 including the lungs in some settings⁵⁸. Moreover, Cruz *et al.* documented persistent
9 immunological alterations in PASC patients, including redistribution of CD8⁺ T cells expressing
10 the mucosal homing β 7 Integrin and higher levels of plasma IgA against SARS-CoV-2 S and N
11 proteins, suggesting possible mucosal involvement⁶⁰.

12
13 Interrogating cells involved in or derived from germinal center (GC) responses including virus-
14 specific B cells, antibody secreting cells (ASC), and T follicular helper (Tfh) CD4⁺ T cells could also
15 provide insights about SARS-CoV-2 antigen or RNA persistence in PASC. In other settings, for
16 example in studies of viral RNA persistence after alphavirus or persistent measles virus
17 infection, a characteristic feature is either local tissue residence of virus-specific antibody-
18 secreting cells (ASCs)^{61,62} and/or ongoing GC reactions and production of ASCs⁶³. Ongoing
19 stimulation of immune responses by viral RNA long after acute disease has resolved results in
20 the continued appearance of ASCs and circulating Tfh cells in peripheral blood and maturation
21 of plasma antibody avidity⁶³. Persistent influenza virus antigen in lung-draining lymph nodes is
22 also thought to drive GC responses that can last for months^{64 65 66}. Overall, these data suggest
23 that GC B cells and/or Tfh cells might be used as biosensors to infer the persistent viral antigens
24⁴⁹.

25 There is some evidence that SARS-CoV-2 can persist in lymphoid tissues where GC are located
26³⁰. While not performed in PASC (symptoms were not measured as part of the study) Xu *et al.*
27 identified persistent expansion of GC and antiviral lymphocyte populations associated with
28 interferon (IFN)- γ -type responses in pharyngeal lymphoid tissues (tonsil and adenoid) collected
29 via surgery from non-vaccinated COVID-19-convalescent children³⁷. SARS-CoV-2 nucleocapsid
30 RNA was identified in 15 out of 22 tonsil, and 7 out of 9 adenoid samples, despite negative
31 nasopharyngeal swab RT-PCRs at the time of surgery. In 4 cases where tissue was examined,
32 the last positive nasopharyngeal swab RT-PCR had been ~100-300 days before surgery. Viral
33 RNA copies significantly correlated with the percentages of S1⁺RBD⁺ B cells among GC B cells in
34 tonsil tissue, suggesting that SARS-CoV-2 antigen persistence contributed to the prolonged
35 lymphoid and GC responses. How such persisting GC responses relate to PASC remains to be
36 explored.

37 38 **Mechanisms of disease**

39
40 The persistence of SARS-CoV-2 RNA and/or proteins in PASC reservoir sites could drive disease
41 via several non-mutually exclusive mechanisms (Figure 1). Persistent viral RNA and/or protein
42 might engage host pattern-recognition receptors, provoking cytokine production and
43 inflammation. Repeated recognition of persistent protein by host adaptive immune cells could

1 result in effector activity, exhaustion and/or altered differentiation of virus-specific T cells and B
2 cells over time any of which could contribute to tissue damage or pathology.

3
4 Active SARS-CoV-2 replication, or persistence or production of viral proteins and/or RNA, could
5 also be directly cytopathic. As many cells express the receptors necessary for virus entry, direct
6 damage could occur in a wide array of tissues or organ systems. Infection of neurons or nerves,
7 for example, could lead to direct damage in the central or peripheral nervous systems.
8 However, SARS-CoV-2 RNA or protein could drive PASC pathology via mechanisms that do not
9 result in overt inflammation or tissue cytopathology. Multiple SARS-CoV-2 proteins can
10 downregulate the host innate immune response⁶⁷, suggesting that local responses may be
11 disabled rather than activated. SARS-CoV-2 proteins are also capable of modulating host
12 metabolic, genetic, and epigenetic factors⁶⁸ to dysregulate the activity of host signaling
13 pathways in a manner that could drive a range of chronic symptoms in the absence of overt
14 cytopathology.

15
16 A SARS-CoV-2 reservoir in PASC could also contribute to coagulation and vasculature-related
17 issues. Pretorius *et al.* identified fibrin/amyloid microclots resistant to fibrinolysis (indicative of
18 hypercoagulation) in PASC platelet-poor plasma (PPP)⁶⁹. They also showed that addition of the
19 SARS-CoV-2 S1 protein to healthy PPP resulted in structural changes to fibrinogen (including
20 resistance to trypsinization) similar to the fibrin deposits identified in the microclots⁷⁰. Another
21 study demonstrated that the SARS-CoV-2 spike protein can bind to fibrinogen and induce
22 structurally abnormal blood clots with heightened proinflammatory activity⁷¹. Thus, SARS-CoV-
23 2 S1 or spike protein in PASC plasma may directly contribute to microclot formation, localized
24 tissue fibrin accumulation, and related vascular issues. In fact, SARS-CoV-2 spike protein has
25 been identified inside COVID-19 thrombi⁷², suggesting it might be possible for microclots to
26 entrap viral proteins. Entrapment of SARS-CoV-2 protein inside microclots could represent
27 another reason that SARS-CoV-2 protein might not be easily identified in the plasma of PASC
28 patients with a viral reservoir. Persistence of spike antigen in plasma could also trigger
29 formation of proinflammatory immune complexes and/or NETs that can contribute to clotting
30 processes. For example, one study found that addition of spike protein to convalescent COVID-
31 19 plasma containing SARS-CoV-2 antibodies led to the formation of antigen:antibody immune
32 complexes that induced significant NETosis compared with convalescent COVID-19 plasma
33 alone⁷³.

34
35 Dysregulation of the immune response by SARS-CoV-2 reservoir could also facilitate the
36 reactivation of latent infections. Expression of SARS-CoV-2 proteins that downregulate host
37 interferon signaling^{74 75} – signaling central to successful control of persisting viral infections -
38 may be particularly detrimental in this regard. Indeed, reactivation of latent herpesvirus, such
39 as Epstein-Barr virus (EBV), has been associated with PASC^{76 59 77 78}. However, the relationship
40 between herpesvirus reactivation in PASC and potential persistence of SARS-CoV-2 in the same
41 patient/cohort remains incompletely understood.

42
43 **SARS-CoV-2 reservoir may contribute to microbiome imbalance**

1 RNA virus infections correlate with microbiome alterations and the outgrowth of opportunistic
2 microbes ⁷⁹. These observations suggest that dysregulation of the host immune responses by
3 SARS-CoV-2 in tissue could negatively impact host microbiome diversity or activity in the same
4 or distant body sites. Because microbiome-derived metabolites are major regulators of host
5 immune, metabolic, and hormonal signaling, microbiome imbalance or dysbiosis can drive a
6 range of pathological processes ^{79 80}. Microbiome activity also contributes to priming of the
7 immune system and the production of compounds that disable pathogens. Thus, it is possible
8 that microbiome dysbiosis could predispose to an altered SARS-CoV-2 infection. For example,
9 women with vaginal microbiome dysbiosis are more likely to acquire HIV ⁸¹. Microbiome
10 dysbiosis has been reported in PASC ⁸², but thus far has not been studied in concert with SARS-
11 CoV-2 persistence in the same body site.

12
13 SARS-CoV-2 reservoir and/or microbiome dysbiosis in the gastrointestinal tract, oral cavity, or
14 other body sites can be accompanied by low-grade local inflammation that promotes
15 dysfunction or breakdown of epithelial barriers. This increased epithelial barrier permeability
16 facilitates the translocation of SARS-CoV-2 proteins or microbial products into the bloodstream,
17 where they can drive or sustain inflammatory processes ⁸³. For example, Yonker *et al.* found
18 that children with MIS-C harbored SARS-CoV-2 RNA in stool weeks after initial infection ⁸⁴. This
19 RNA detection was accompanied by SARS-CoV-2 spike protein in plasma and significantly
20 increased release of zonulin - a biomarker of intestinal permeability ^{85,86}. These findings suggest
21 that in MIS-C, prolonged persistence of SARS-CoV-2 in the gastrointestinal tract drives zonulin-
22 instigated permeability of the mucosal barrier, with subsequent increased trafficking of SARS-
23 CoV-2 protein from the gut into the bloodstream, leading to hyperinflammation ⁸⁷. A similar
24 phenomenon might occur in patients with PASC.

25 26 **SARS-CoV-2 reservoir and cross-reactive autoimmunity**

27
28 SARS-CoV-2 can induce antibody responses that are cross-reactive with host proteins, with at
29 least one mechanism being molecular mimicry (sequence homology between viral antigens and
30 host receptors or proteins). For example, Kreye *et al.* identified high-affinity SARS-CoV-2-
31 neutralizing antibodies that cross-reacted with mammalian heart, gut, lung, kidney, and brain
32 self-antigens ⁸⁸. Autoreactive T cells and antibodies can be induced during acute infection, but
33 also may be continually promoted by a persistent SARS-CoV-2 reservoir. Recent evidence shows
34 that EBV is an example of a persistent virus that can drive molecular mimicry-based
35 autoimmunity. In an analysis of multiple sclerosis cerebrospinal fluid, Lanz *et al.* demonstrated
36 molecular mimicry between EBV protein nuclear antigen 1 (EBNA1) and the central nervous
37 system protein glial cell adhesion molecule (GlialCAM)⁸⁹. Given the connections between EBV
38 and PASC mentioned above, these observations further highlight the need for additional studies
39 on the relationship between the two viruses.

40 41 **SARS-CoV-2 reservoir may alter vagus nerve signaling**

42
43 A SARS-CoV-2 reservoir could also contribute to non-specific PASC symptoms including fatigue,
44 trouble concentrating, muscle and joint pain, sleep dysfunction, anxiety, depression, loss of

1 appetite, and autonomic dysfunction⁹⁰. These symptoms overlap with the sickness response
2 (called ‘sickness behavior’ in animal models) that reflects the subjective and behavioral
3 component of innate immunity and is largely mediated by signaling of the vagus nerve^{90 91}.
4 Tens of thousands of afferent vagus nerve branches innervate all major trunk organs with
5 chemoreceptor terminals, which collectively act as a sensitive and diffuse neuroimmune
6 sensory organ for the central nervous system. These branches can detect highly localized
7 paracrine immune signaling such as cytokine activation even in the absence of a systemic
8 circulating immune response⁹⁰, triggering glial activation and neuroinflammation on the brain
9 side of the blood brain barrier and the sickness response. The persistence of a SARS-CoV-2
10 reservoir in body sites densely innervated by the vagus nerve (e.g., gut, lung, bronchial tubes,
11 etc.) - or direct infection of the vagus nerve⁹² as has been shown in autopsy studies^{93 94}- might
12 activate localized paracrine signaling, leading to ongoing sickness response symptoms in
13 infected individuals.

14

15 **SARS-CoV-2 reservoir and neurodegenerative sequelae**

16

17 Direct infiltration and persistence of SARS-CoV-2 in the CNS is also a potential driver of
18 neuroinflammation and/or cognitive, neurological, and psychiatric symptoms in individuals with
19 PASC. SARS-CoV-2 neuroinvasion potential has been shown in organoid and animal models^{95,97}
20 and in several autopsy studies that prioritized short postmortem intervals^{31,94}. Such
21 neuroinvasion may be relevant to the apparent post-acute COVID-19 sequela of increased
22 Alzheimer's disease (AD) incidence. Wang *et al.* found that older adults (age ≥ 65 years) had a
23 significantly increased risk for a new AD diagnosis within 360 days after acute COVID-19⁹⁶. A
24 separate autopsy study demonstrated increased amyloid beta (A β) plaque deposition in brain
25 tissue obtained from severely ill, hospitalized COVID-19 patients younger than 60 years old⁹⁷.
26 AD amyloid beta “plaques” can function as an antimicrobial peptide that forms as part of the
27 host innate immune response towards pathogens in brain tissue. In a series of *in vitro* and
28 animal experiments, Eimer *et al.* demonstrated A β accumulation via extracellular trap
29 agglutination in response to bacteria, fungi, and viruses (including HSV-1)^{98 99 100}. Thus, SARS-
30 CoV-2 persistence in the CNS - or CNS reactivation of other pathogens such as herpesviruses
31 post-COVID - might also contribute to activation of an evolutionarily conserved role for A β as an
32 antimicrobial peptide, increasing both short and long-term risk for AD.

33

34 **Major areas of investigation**

35

36 Many aspects of SARS-CoV-2 persistence in PASC and the impact of viral activity on related
37 biological factors require further study. More research is needed to understand if SARS-CoV-2
38 RNA identified in PASC tissue samples months after acute COVID-19 is actively transcribed,
39 translated, replicated, and/or is infectious. SARS-CoV-2 protein detection could indicate
40 replicating virus and/or transcribable viral RNA (Figure 2). However, the persistence of both
41 SARS-CoV-2 protein and RNA after acute COVID-19 may differ by cell type or anatomical
42 location due to differences in the local immune environment and/or the lifespan or turnover of
43 infected cells. For example, lymph node B cell follicles can harbor antigen for extended periods
44 of time as antigen-antibody complexes on follicular dendritic cells¹⁰¹. However, long-term

1 persistence of SARS-CoV-2 protein in the absence of replicating virus is much less likely in cell
2 types that experience rapid turnover – such as intestinal epithelial cells. Autopsy studies and
3 additional tissue biopsy studies - which together offer unparalleled access to broad tissue types
4 - must be performed in PASC so that these potentially distinct features of SARS-CoV-2 reservoir
5 sites can be better delineated. Such efforts would be greatly facilitated by a PASC registry
6 combined with a coordinated autopsy research program.

7
8 Viral culture is the gold standard for identification of infectious SARS-CoV-2 but has not been
9 successful in post-COVID samples^{38 33}. However, viral growth from such samples is challenging
10 for many reasons including susceptibility of the cell line to different strains, presence of
11 neutralizing antibody in the sample, and limiting amounts of material available. In addition,
12 multiple biological mechanisms can suppress the production of infectious virions to facilitate
13 the survival of infected cells despite viral RNA persistence. For example, viral mutations can
14 accumulate that decrease virion assembly or decrease RNA synthesis, while host cells engage
15 antiviral immune responses that facilitate infected cell survival¹⁰². Indeed, acquisition of viral
16 mutations is a well-established mechanism that facilitates the persistence of certain RNA
17 viruses including coronaviruses¹⁰³.

18
19 Further study is also required to better understand if SARS-CoV-2 RNA and/or protein
20 persistence in certain PASC tissues or body fluids may differ based on viral variant (e.g., delta
21 versus omicron), and the unique manner by which different viral variants may evade the host
22 immune response. For example, SARS-CoV-2 can downregulate major histocompatibility
23 complex (MHC) class I expression to evade CD8⁺ T cell recognition¹⁰⁴, with more effective
24 evasion by omicron subvariants¹⁰⁵. Suboptimal antiviral host responses typified by early
25 induction of non-neutralizing antibodies and anti-inflammatory post-translational modification
26 of immunoglobulin Fc regions might also facilitate SARS-CoV-2 persistence in PASC.

27
28 The questions in Box 1 highlight major research areas of opportunity that should provide
29 further clarity on the role of a SARS-CoV-2 reservoir in the PASC disease process. Diverse
30 approaches and methodologies must be employed to address these central research questions.
31 These include autopsy studies, imaging studies, tissue biopsy studies, use of ultrasensitive
32 assays to identify viral protein, use of immune cells as biosensors of SARS-CoV-2 persistence,
33 and other methods (see Supplementary Note).

34 35 **Biomarker and therapeutic targets for PASC clinical trials**

36
37 Research on SARS-CoV-2 reservoir and related biological factors in PASC will enable
38 identification of 1) biomarkers for improved PASC diagnosis; 2) biomarkers that serve as
39 primary outcome measures for PASC clinical trials; 3) therapeutic candidates for PASC clinical
40 trials. Potential therapeutics for the treatment of SARS-CoV-2 reservoir in PASC include direct-
41 acting and host-directed antivirals and immunomodulators that can boost the immune
42 response (e.g., interferons and monoclonal antibodies). Early case reports suggest that SARS-
43 CoV-2 antivirals may benefit certain PASC individuals¹⁰⁶. For example, a PASC patient reported
44 resolution of symptoms and a return to pre-COVID-19 health function after a 5-day course of

1 the SARS-CoV-2 antiviral nirmatrelvir-ritonavir (Paxlovid)¹⁰⁷. Such anecdotal cases highlight the
2 need for rigorous clinical trials designed to address this hypothesis, and multiple double-blind,
3 randomized clinical trials of direct-acting antivirals such as Paxlovid for the proposed treatment
4 of SARS-CoV-2 reservoir in PASC are planned or underway (see [Clinicaltrials.gov](https://clinicaltrials.gov) NCT05576662,
5 NCT0566809, NCT05595369).

6
7 However, some forms of antiviral treatment may only show benefit if SARS-CoV-2 is actively
8 replicating and spreading from cell to cell. It is also possible that a single course of approved
9 SARS-CoV-2 antivirals is not adequate to fully address viral persistence in all relevant PASC
10 cases. Indeed, even for acute infection viral rebound after treatment due to incomplete viral
11 clearance is well documented. Therefore, treatment of a SARS-CoV-2 reservoir in PASC may
12 require longer dosing periods to achieve maximum efficacy. Moreover, combining more than
13 one antiviral both increases efficacy and reduces the risk of resistance. For example, Cherry *et al.*
14 demonstrated that combining pyrimidine biosynthesis inhibitors with antiviral nucleoside
15 analogues synergistically inhibits SARS-CoV-2 infection *in vitro* and *in vivo* against emerging
16 strains of SARS-CoV-2 during acute respiratory infection¹⁰⁸. Regimens for other RNA viruses
17 capable of persistence (e.g., HIV, HCV) require multiple drugs for robust long-term benefit.

18
19 Treatment with antivirals or combinations of antivirals and immune-modulating agents during
20 acute COVID-19 may also prevent PASC by decreasing or eliminating virus that might otherwise
21 persist in a reservoir. Acute COVID-19 antiviral clinical trials should consequently be designed to
22 capture the impact of treatment on PASC development. For example, Xie *et al.* estimated the
23 effect of the antiviral nirmatrelvir (versus control) on covariate-standardized hazard ratio and
24 absolute risk reduction of a prespecified panel of 12 post-acute COVID-19 outcomes after 90
25 days¹⁰⁹. They found that in individuals with SARS-CoV-2 infection with at least 1 risk factor for
26 progression to severe COVID-19 illness, nirmatrelvir treatment within five days of a positive
27 COVID-19 test was associated with reduced risk of PASC regardless of history of prior infection
28 and vaccination status.

29
30 Research findings should also inform how therapies against SARS-CoV-2 might best be
31 combined with other treatment modalities in PASC. These therapies could include herpesvirus
32 antivirals, microbiome-based therapeutics, anticoagulant medications, and vagus nerve
33 stimulation. Some of these therapeutics may be tailored to the site of the reservoir. For
34 example, treatment of a MIS-C patient with larazotide to restore gut epithelial barrier
35 permeability resulted in a decrease in plasma SARS-CoV-2 spike antigen levels and
36 inflammatory markers, accompanied by clinical improvement⁸⁴¹¹⁰. Similar approaches aimed at
37 restoring normal gut barrier permeability might also be employed in PASC in concert with
38 antivirals or immunomodulators.

39 **Conclusion**

40
41
42 SARS-CoV-2 reservoir may drive inflammatory, coagulation, microbiome, neuroimmune, and
43 other abnormalities in PASC. Future research should focus on determining if SARS-CoV-2
44 persistence varies by cell type or body site, by viral variant, and should further delineate

1 mechanisms by which a SARS-CoV-2 evades immune detection or elimination to persist in
2 patient tissue. Factors that differentiate SARS-CoV-2 persistence in PASC from persistence in
3 asymptomatic individuals should be explored. More research is needed to understand if SARS-
4 CoV-2 RNA in PASC reservoir sites is being actively transcribed, translated, replicated, and/or is
5 infectious. A PASC autopsy program and additional PASC tissue biopsy studies are required to
6 best address these central research questions.

7
8 More broadly, the study of SARS-CoV-2 reservoir and related biological factors in PASC may
9 inform the identification of disease mechanisms, biomarkers, and therapeutics for other
10 chronic conditions increasingly tied to persistent viral infection. These include myalgic
11 encephalomyelitis/chronic fatigue syndrome (ME/CFS)¹¹¹, Alzheimer's disease⁹⁹, autoimmune
12 diseases such as multiple sclerosis^{89 112} and systemic lupus erythematosus¹¹³. While a growing
13 body of evidence connects the pathogenesis of these conditions to the activity of persistent
14 DNA viruses, it is possible that RNA viruses previously studied primarily for their ability to drive
15 acute illness could also contribute to disease in a chronic capacity. Synergistic approaches
16 developed to characterize a SARS-CoV-2 reservoir in PASC could be rapidly incorporated into
17 the study of chronic RNA virus activity in these related conditions to inform a deeper
18 understanding of shared biological mechanisms.

19 20 **Acknowledgements**

21
22 We thank all members of the Wherry laboratory and PolyBio Research Foundation for helpful
23 discussions and critical analysis of the manuscript. PolyBio Research Foundation thanks its
24 generous donors including Balvi for support of the work. Work in the Wherry lab is supported
25 by the National Institutes of Health grants AI155577 (EJW), AI115712 (EJW), AI117950 (EJW),
26 AI108545 (EJW), AI082630 (EJW), and CA210944 (EJW). Work in the Wherry lab is also
27 supported by the Parker Institute for Cancer Immunotherapy and PolyBio Research Foundation.

28 29 **Author contributions statement**

30
31 A.D.P., M.B.V., S.A., K.B., B.P.B, M.B., S.C, D. S.C., H.E.D., C.L.D., S.D., W.E., E.W.E., A.F., M.F.,
32 L.N.G., D.G., T.J.H., A.I., D.I., M.L., S.M., M.P., M.J.P., E.P., D.A.P, D.P., R.H.S., G.S.T., R.E.T.,
33 H.F.V., L.M.Y., and E.J.W. contributed to writing and editing. A.D.P. wrote the initial draft of the
34 manuscript and conceived of the figures and tables. E.J.W. supervised and edited writing of the
35 manuscript. M.B.V. edited and improved the manuscript and conceived of Figure 2.

36 37 **Competing interest statement**

38
39 A.D.P. has received consulting fees from Enanta Pharmaceuticals outside the submitted work.
40 S.A. has received honoraria for lectures and educational events from Gilead, AbbVie, MSD and
41 Biogen, and reports grants from Gilead and AbbVie. E.W.E. has received Grant Support/Research
42 Funding from the NIH/VA, is an unfunded Investigator with Baricitinib on COVID-19 studies
43 funded by Eli Lilly, and has lectured at events related to sedation in the ICU sponsored by Pfizer.

1 M.F. reports a relationship with Mars that includes board membership. L.N.G. reports receiving
 2 grants from Pfizer and advisory fees from UnitedHealthcare. D.G. is a member of scientific
 3 advisory committees for GSK, Merck and Takeda Pharmaceuticals. T.J.H. consults for Roche and
 4 received grant support from Merck. A.I. co-founded and consults for RIGImmune, Xanadu Bio and
 5 PanV; consults for Paratus Sciences, InvisiShield Technologies; and is a member of the Board of
 6 Directors of Roche Holding Ltd. M.J.P. has received consulting fees from Gilead Sciences and
 7 AstraZeneca, outside the submitted work. R.P. founded Biocode Technologies and hold a patent
 8 for detection of microclots in blood samples. E.J.W. is a member of the Parker Institute for Cancer
 9 Immunotherapy which supports cancer immunology research in his laboratory. E.J.W. is an
 10 advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics, Related
 11 Sciences, Santa Ana Bio, Synthekine, and Surface Oncology. E.J.W. is a founder of and holds stock
 12 in Surface Oncology, Danger Bio, and Arsenal Biosciences. The authors declare that they have no
 13 known competing financial interests or personal relationships that could have appeared to
 14 influence the work reported in this paper.

15

16 **Table 1:**

17

18 **Identification of SARS-CoV-2 RNA and protein post COVID-19**

19

20

21

RNA Protein PASC symptoms Location

22

23

24 **Tissue - biopsy**

25

26 Goh *et al*³⁹. √ S, N √ Appendix, skin, and breast tissues 163 and 426
 27 days post-

28 COVID-19

29 Zollner *et al*³⁸. √ N √ Gut mucosa/epithelium tissue ~7 months post-
 30 COVID-19

31

32 deMelo *et al*²⁷. √ N √ Olfactory neuroepithelium tissue 110–
 33 196 days post-

34 COVID-19

35 Gaebler *et al*.³³ √ N No Intestinal tissue ~4 months post-COVID-19

36 Cheung *et al*¹⁴. √ S, N NM Colon, appendix, ileum, hemorrhoid,
 37 liver,

38 gallbladder, lymph node 9-180 days
 39 post-COVID-19

40 Hany *et al*²⁹. NM N NM Gastric and gallbladder tissues 274-380 days
 41 post-COVID-19

42 Miura *et al*³⁰. √ N No Adenoid tonsil, adenoid tissue, nasal
 43 cytobrush, and

1	nasal wash from children with				
2	no documented COVID-19 or upper airway				
3	infection in the month before collection				
4	Xu <i>et al</i> ³⁷ .	√	NM	No	Child adenoid and tonsil tissue up to 303 days
5					post-COVID-19
6					
7	Tissue - autopsy				
8					
9	Stein <i>et al</i> ³¹ .	√	N	NM	Dozens of human body and brain tissue types at
10					least 31 days
11	and up to 230 days post-COVID19				
12	Roden <i>et al</i> ³² .	√	NM	NM	Lung tissue up to 174 days post-COVID-19
13	Bussani <i>et al</i> ²⁴ .	√	S, N	NM	Bronchial cartilage chondrocytes, para bronchial
14					gland epithelial
15	cells, vascular pericytes,				
16	endothelial cells average 105.5 days post-				
17	COVID-19				
18	Böszörményi <i>et al</i> ²⁵ .	√	NM	NM	Macaque extrapulmonary tissues including
19	heart,				respiratory
20	tract, surrounding lymph nodes, salivary gland, and conjunctiva 5-6				
21	weeks post-COVID-19				
22	Rendiero <i>et al</i> ¹¹⁵ .		NM S	NM	Lung tissue up to 359 days post-COVID-19
23					
24					
25	Stool				
26					
27	Natarajan <i>et al</i> ¹¹⁶ .	√	NM	√	Stool up to 230 days post-COVID-19
28	Yonker <i>et al</i> ⁸⁴ .	√	S, N	√	RNA in stool of children with MIS-C 13–62 days
29	post-				COVID-19, S
30	and N protein in plasma				
31	Jin <i>et al</i> ¹¹⁷ .	√	S	NM	Neonatal stool in infants born to mothers
32					whose COVID-
33	19 symptoms resolved more than 10 weeks prior to delivery				
34					
35	Blood				
36					
37	Schultheiß <i>et al</i> ⁴⁰ .	NM	S1	√	Plasma at a median time of 8 months post-
38					COVID-19
39	Swank <i>et al</i> ⁴¹ .	NM	S, S1, N	√	Plasma up to 12 months post-COVID-19
40	Peluso <i>et al</i> ⁴⁴ .	NM	S1, N	√	Plasma neuron-derived extracellular
41					vesicles 35-84
42	days post-COVID-19				
43	Peluso <i>et al</i> ⁴² .	NM	S1, S, N	√	Plasma up to 16 months post-COVID-19
44	Craddock <i>et al</i> ⁴⁵ .	√	S	√	Spike linked to extracellular vesicles in samples
45					obtained at
46	least 8-12 weeks (up to 1 year)				
47	post-COVID-19				

1 Tejerina *et al*¹¹⁸. ✓ NM ✓ Plasma at a median time of 55 days post-COVID-
2 19 (also found
3 in stool/urine at the same median timepoint)

4
5
6

Box 1:

- Which PASC cell and tissue types harbor SARS-CoV-2 RNA or protein? Is there a preference for persistence in certain cell or tissue types?
- Is SARS-CoV-2 RNA identified in PASC samples transcriptionally active, translating, replicating, or infectious?
- Is the presence of a SARS-CoV-2 reservoir sufficient to drive PASC symptoms? Are SARS-CoV-2 RNA and proteins also identified in samples collected from post-COVID-19 patients without PASC? If yes, what factors differentiate SARS-CoV-2 persistence in PASC from persistence in asymptomatic individuals?
- Do particular classes of symptoms tend to be driven by the location of the reservoir, i.e., dyspnea from a lung reservoir, GI symptoms from a gut reservoir?
- Do measurements of SARS-CoV-2 protein or antibody responses in body fluids correlate with SARS-CoV-2 persistence in tissue?
- Can the transcriptional program of circulating immune cells be used as a biosensor of SARS-CoV-2 persistence in tissue? Does T cell exhaustion correlate with SARS-CoV-2 persistence in PASC?
- Are neutralizing antibody responses qualitatively different in patients with PASC?
- By what mechanisms can SARS-CoV-2 evade immune detection? Do such mechanisms differ by cell or tissue type, or by viral variant? Do viral mutations and selection contribute to persistence?
- Can the spike protein travel via extracellular vesicles into the bloodstream?
- Does SARS-CoV-2 reservoir or protein contribute to fibrin/amyloid microclotting, platelet activation, or related vasculature issues in PASC?
- Does SARS-CoV-2 reservoir in PASC correlate with the reactivation of other pathogens such as herpesviruses?
- Does SARS-CoV-2 reservoir in PASC correlate with changes in Human Endogenous Retrovirus (HERV) activity?
- Can a SARS-CoV-2 reservoir alter the local transcriptome or epigenome?
- Does SARS-CoV-2 reservoir in PASC correlate with the disruption of microbiome composition or activity? If so, is disruption a cause or consequence of PASC?
- Is SARS-CoV-2 reservoir associated with host epithelial barrier breakdown in PASC? Does this facilitate the translocation viral protein or bacterial/fungal organisms into blood?
- Can SARS-CoV-2 persistence or the reactivation of other latent pathogens lead to cross-reactive antibody responses in PASC blood or tissue?

7
8
9

10 **Figure legends**

1
2 Figure 1: Mechanisms by which a SARS-CoV-2 reservoir may contribute to PASC. BioRender
3 licensed software was not used to create the figure.

4
5 Figure 2: Components of SARS-CoV-2 measured in persistence studies. BioRender licensed
6 software was not used to create the figure.

7
8 **Table 1:** $\sqrt{\quad}$ = identified, No - not present, NM =not measured, S= spike protein, N= nucleocapsid
9 protein

10
11 **References:**

12
13 1. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An
14 Overview of Biological Factors That May Contribute to Persistent Symptoms. *Front*
15 *Microbiol.* 2021;12. doi:10.3389/FMICB.2021.698169
16 2. National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022–
17 2023. Long COVID. Published online 2023.
18 3. Cutler DM. The Economic Cost of Long COVID: An Update (2023). *White Paper*. Accessed
19 March 27, 2023. [https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-](https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf)
20 [22.pdf](https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf)
21 4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
22 recommendations. *Nat Rev Microbiol.* Published online 2023. doi:10.1038/S41579-022-
23 00846-2
24 5. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international
25 cohort: 7 months of symptoms and their impact. *EClinicalMedicine.* 2021;38.
26 doi:10.1016/J.ECLINM.2021.101019
27 6. Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-hospitalized
28 individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID
29 programme. *Eur Heart J.* 2022;43(11):1124-1137. doi:10.1093/EURHEARTJ/EHAB914
30 7. Peluso MJ, Daniel Kelly J, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute
31 Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort
32 Description and Approaches for Measurement. *Open Forum Infect Dis.* 2022;9(2).
33 doi:10.1093/OFID/OFAB640
34 8. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, et al. Long-COVID in children and
35 adolescents: a systematic review and meta-analyses. *Sci Rep.* 2022;12(1).
36 doi:10.1038/S41598-022-13495-5
37 9. Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 Conditions Among Children 90
38 Days After SARS-CoV-2 Infection. *JAMA Netw Open.* 2022;5(7):E2223253.
39 doi:10.1001/JAMANETWORKOPEN.2022.23253
40 10. Centers for Disease Control and Prevention. Health department-reported cases of
41 multisystem inflammatory syndrome in children (MIS-C) in the United States.
42 11. Keita AK, Vidal N, Toure A, et al. A 40-month follow-up of Ebola virus disease survivors in
43 Guinea (Postebogui) reveals long-term detection of Ebola viral ribonucleic acid in semen
44 and breast milk. *Open Forum Infect Dis.* 2019;6(12). doi:10.1093/ofid/ofz482

- 1 12. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola Virus in Ocular Fluid during
2 Convalescence. *New England Journal of Medicine*. 2015;372(25):2423-2427.
3 doi:10.1056/NEJMOA1500306/SUPPL_FILE/NEJMOA1500306_DISCLOSURES.PDF
- 4 13. Sow MS, Group for the PS, Etard JF, et al. New Evidence of Long-lasting Persistence of
5 Ebola Virus Genetic Material in Semen of Survivors. *J Infect Dis*. 2016;214(10):1475-1476.
6 doi:10.1093/INFDIS/JIW078
- 7 14. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika Virus in Body Fluids — Final
8 Report. *New England Journal of Medicine*. 2018;379(13):1234-1243.
9 doi:10.1056/NEJMOA1613108/SUPPL_FILE/NEJMOA1613108_PRELIM.PDF
- 10 15. Chia JKS, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus
11 infection of the stomach. *J Clin Pathol*. 2008;61(1):43-48. doi:10.1136/jcp.2007.050054
- 12 16. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is
13 associated with progressive cardiac dysfunction. *Circulation*. 2005;112(13):1965-1970.
14 doi:10.1161/CIRCULATIONAHA.105.548156
- 15 17. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human
16 immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase
17 chain reaction. *J Infect Dis*. 2001;183(4):532-538. doi:10.1086/318533
- 18 18. Riddell MA, Moss WJ, Hauer D, Monze M, Griffin DE. Slow clearance of measles virus RNA
19 after acute infection. *J Clin Virol*. 2007;39(4):312-317. doi:10.1016/J.JCV.2007.05.006
- 20 19. Dokubo EK, Wendland A, Mate SE, et al. Persistence of Ebola virus after the end of
21 widespread transmission in Liberia: an outbreak report. *Lancet Infect Dis*.
22 2018;18(9):1015-1024. doi:10.1016/S1473-3099(18)30417-1
- 23 20. Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. Post-ebola syndrome,
24 Sierra Leone. *Emerg Infect Dis*. 2016;22(4):641-646. doi:10.32032/EID2204.151302
- 25 21. Subissi L, Keita M, Mesfin S, et al. Ebola Virus Transmission Caused by Persistently
26 Infected Survivors of the 2014-2016 Outbreak in West Africa. *J Infect Dis*.
27 2018;218(suppl_5):S287-S291. doi:10.1093/INFDIS/JIY280
- 28 22. Keita AK, Koundouno FR, Faye M, et al. Resurgence of Ebola virus in 2021 in Guinea
29 suggests a new paradigm for outbreaks. *Nature* 2021 597:7877. 2021;597(7877):539-
30 543. doi:10.1038/s41586-021-03901-9
- 31 23. Russell K, Hills SL, Oster AM, et al. Male-to-Female Sexual Transmission of Zika Virus-
32 United States, January-April 2016. *Clin Infect Dis*. 2017;64(2):211-213.
33 doi:10.1093/CID/CIW692
- 34 24. Bussani R, Zentilin L, Correa R, et al. Persistent SARS-CoV-2 infection in patients
35 seemingly recovered from COVID-19. *J Pathol*. 2023;259(3). doi:10.1002/PATH.6035
- 36 25. Böszörményi KP, Stammes MA, Fagrouch ZC, et al. The post-acute phase of sars-cov-2
37 infection in two macaque species is associated with signs of ongoing virus replication and
38 pathology in pulmonary and extrapulmonary tissues. *Viruses*. 2021;13(8).
39 doi:10.3390/V13081673/S1
- 40 26. Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE. Persistent
41 alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.
42 *medRxiv*. Published online November 29, 2022:2022.11.28.22282811.
43 doi:10.1101/2022.11.28.22282811

- 1 27. de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with
2 viral persistence and inflammation in human olfactory epithelium and brain infection in
3 hamsters. *Sci Transl Med*. 2021;13(596). doi:10.1126/SCITRANSLMED.ABF8396
- 4 28. Cheung CCL, Goh D, Lim X, et al. Residual SARS-CoV-2 viral antigens detected in GI and
5 hepatic tissues from five recovered patients with COVID-19. *Gut*. Published online 2021.
6 doi:10.1136/gutjnl-2021-324280
- 7 29. Hany M, Zidan A, Gaballa M, et al. Lingering SARS-CoV-2 in Gastric and Gallbladder
8 Tissues of Patients with Previous COVID-19 Infection Undergoing Bariatric Surgery. *Obes*
9 *Surg*. 2022;1:1-10. doi:10.1007/S11695-022-06338-9/FIGURES/3
- 10 30. Miura CS, Lima TM, Martins RB, et al. Asymptomatic SARS-COV-2 infection in children's
11 tonsils. *Braz J Otorhinolaryngol*. 2022;88:9. doi:10.1016/J.BJORL.2022.10.016
- 12 31. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human
13 body and brain at autopsy. *Nature* 2022 612:7941. 2022;612(7941):758-763.
14 doi:10.1038/s41586-022-05542-y
- 15 32. Roden AC, Boland JM, Johnson TF, et al. Late Complications of COVID-19: A Morphologic,
16 Imaging, and Droplet Digital Polymerase Chain Reaction Study of Lung Tissue. *Arch Pathol*
17 *Lab Med*. Published online 2022. doi:10.5858/arpa.2021-0519-sa
- 18 33. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.
19 *Nature*. 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w
- 20 34. Aid M, Abbink P, Larocca RA, et al. Zika Virus Persistence in the Central Nervous System
21 and Lymph Nodes of Rhesus Monkeys. *Cell*. 2017;169(4):610-620.e14.
22 doi:10.1016/j.cell.2017.04.008
- 23 35. Mead PS, Duggal NK, Hook SA, et al. Zika Virus Shedding in Semen of Symptomatic
24 Infected Men. *New England Journal of Medicine*. 2018;378(15):1377-1385.
25 doi:10.1056/nejmoa1711038
- 26 36. Coffin KM, Liu J, Warren TK, Kuhn JH, Bavari S, Zeng Correspondence X. Persistent
27 Marburg Virus Infection in the Testes of Nonhuman Primate Survivors. *Cell Host Microbe*.
28 2018;24:405-416. doi:10.1016/j.chom.2018.08.003
- 29 37. Xu Q, Milanez-Almeida P, Martins AJ, et al. Adaptive immune responses to SARS-CoV-2
30 persist in the pharyngeal lymphoid tissue of children. *Nature Immunology* 2022.
31 Published online December 19, 2022:1-14. doi:10.1038/s41590-022-01367-z
- 32 38. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen
33 Persistence in Inflammatory Bowel Diseases. *Gastroenterology*. 2022;163(2):495-506.e8.
34 doi:10.1053/J.GASTRO.2022.04.037
- 35 39. Goh D, Lim JCT, Fernández SB, et al. Case report: Persistence of residual antigen and RNA
36 of the SARS-CoV-2 virus in tissues of two patients with long COVID. *Front Immunol*.
37 2022;13:5147. doi:10.3389/FIMMU.2022.939989/BIBTEX
- 38 40. Schultheiß C, Willscher E, Paschold L, et al. Liquid biomarkers of macrophage
39 dysregulation and circulating spike protein 1 illustrate the biological heterogeneity in
40 patients with post-acute sequelae of. doi:10.1101/2022.09.18.22280022
- 41 41. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is
42 associated with post-acute COVID-19 sequelae. *Clin Infect Dis*. Published online
43 September 2, 2022. doi:10.1093/CID/CIAC722

- 1 42. Peluso M, Swank Z, Goldberg S, et al. Plasma-based antigen persistence in the post-acute
2 phase of SARS-CoV-2 infection. *Poster presentation*. Published online 2023.
- 3 43. Ogata AF, Cheng CA, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome
4 Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273
5 Vaccine Recipients. *Clin Infect Dis*. 2022;74(4):715-718. doi:10.1093/CID/CIAB465
- 6 44. Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and Mitochondrial Proteins in
7 Neural-Derived Exosomes of COVID-19. *Ann Neurol*. 2022;91(6):772-781.
8 doi:10.1002/ANA.26350
- 9 45. Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular
10 vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. *J Med*
11 *Virol*. 2023;95(2). doi:10.1002/JMV.28568
- 12 46. Adaken C, Scott JT, Sharma R, et al. Ebola virus antibody decay–stimulation in a high
13 proportion of survivors. *Nature*. 2021;590(7846):468-472. doi:10.1038/s41586-020-
14 03146-y
- 15 47. Nelson AN, Putnam N, Hauer D, Baxter VK, Adams RJ, Griffin DE. Evolution of T Cell
16 Responses during Measles Virus Infection and RNA Clearance. *Scientific Reports 2017 7:1*.
17 2017;7(1):1-10. doi:10.1038/s41598-017-10965-z
- 18 48. Herati RS, Knorr DA, Vella LA, et al. PD-1 directed immunotherapy alters Tfh and humoral
19 immune responses to seasonal influenza vaccine. *Nat Immunol*. 2022;23(8):1183-1192.
20 doi:10.1038/S41590-022-01274-3
- 21 49. Herati RS, Silva LV, Vella LA, et al. Vaccine-induced ICOS+CD38+ circulating Tfh are
22 sensitive biosensors of age-related changes in inflammatory pathways. *Cell Rep Med*.
23 2021;2(5). doi:10.1016/J.XCRM.2021.100262
- 24 50. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC
25 complex on a target cell can elicit a cytolytic T cell response. *Immunity*. 1996;4(6):565-
26 571. doi:10.1016/S1074-7613(00)80483-5
- 27 51. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence
28 alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages
29 of functional impairment. *J Virol*. 2003;77(8):4911-4927. doi:10.1128/JVI.77.8.4911-
30 4927.2003
- 31 52. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation
32 phenotype in different persistent virus infections. *Nat Med*. 2002;8(4):379-385.
33 doi:10.1038/NM0402-379
- 34 53. Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation
35 of a stable mature immunological synapse. *Nat Immunol*. 2004;5(5):524-530.
36 doi:10.1038/NI1058
- 37 54. Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with
38 antigen-specific CD8 T-cell responses. *EBioMedicine*. 2021;64.
39 doi:10.1016/j.ebiom.2021.103230
- 40 55. Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and
41 inflammatory responses in individuals recovering from COVID-19 with and without post-
42 acute symptoms. *Cell Rep*. 2021;36(6). doi:10.1016/J.CELREP.2021.109518

- 1 56. Littlefield KM, Watson RO, Schneider JM, et al. SARS-CoV-2-specific T cells associate with
2 inflammation and reduced lung function in pulmonary post-acute sequelae of SARS-CoV-
3 2. *PLoS Pathog.* 2022;18(5):e1010359. doi:10.1371/JOURNAL.PPAT.1010359
- 4 57. L V, BA H, ZS O, et al. T cell responses to SARS-CoV-2 in people with and without
5 neurologic symptoms of long COVID. *medRxiv.* Published online August 9, 2022.
6 doi:10.1101/2021.08.08.21261763
- 7 58. Yin K, Peluso MJ, Thomas R, et al. Long COVID manifests with T cell dysregulation,
8 inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. *bioRxiv.*
9 Published online February 10, 2023:2023.02.09.527892. doi:10.1101/2023.02.09.527892
- 10 59. Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified through
11 immune profiling. *medRxiv.* Published online August 10, 2022:2022.08.09.22278592.
12 doi:10.1101/2022.08.09.22278592
- 13 60. Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, et al. Post-acute sequelae of COVID-19
14 is characterized by diminished peripheral CD8+ β 7 integrin+ T cells and anti-SARS-CoV-2
15 IgA response. *Nat Commun.* 2023;14(1):1772. doi:10.1038/S41467-023-37368-1
- 16 61. Metcalf TU, Griffin DE. Alphavirus-Induced Encephalomyelitis: Antibody-Secreting Cells
17 and Viral Clearance from the Nervous System. *J Virol.* 2011;85(21):11490.
18 doi:10.1128/JVI.05379-11
- 19 62. Metcalf TU, Baxter VK, Nilaratanakul V, Griffin DE. Recruitment and retention of B cells in
20 the central nervous system in response to alphavirus encephalomyelitis. *J Virol.*
21 2013;87(5):2420-2429. doi:10.1128/JVI.01769-12
- 22 63. Nelson AN, Lin WHW, Shivakoti R, et al. Association of persistent wild-type measles virus
23 RNA with long-term humoral immunity in rhesus macaques. *JCI Insight.* 2020;5(3).
24 doi:10.1172/JCI.INSIGHT.134992
- 25 64. Yewdell WT, Smolkin RM, Belcheva KT, et al. Temporal dynamics of persistent germinal
26 centers and memory B cell differentiation following respiratory virus infection. *Cell Rep.*
27 2021;37(6):109961. doi:10.1016/J.CELREP.2021.109961
- 28 65. Kim TS, Hufford MM, Sun J, Fu YX, Braciale TJ. Antigen persistence and the control of
29 local T cell memory by migrant respiratory dendritic cells after acute virus infection.
30 *Journal of Experimental Medicine.* 2010;207(6):1161-1172. doi:10.1084/JEM.20092017
- 31 66. de Carvalho RVH, Ersching J, Barbulescu A, et al. Clonal replacement sustains long-lived
32 germinal centers primed by respiratory viruses. *Cell.* 2023;186(1):131-146.e13.
33 doi:10.1016/J.CELL.2022.11.031
- 34 67. Rashid F, Xie Z, Suleman M, Shah A, Khan S, Luo S. Roles and functions of SARS-CoV-2
35 proteins in host immune evasion. *Front Immunol.* 2022;13.
36 doi:10.3389/FIMMU.2022.940756
- 37 68. Kee J, Thudium S, Renner DM, et al. SARS-CoV-2 disrupts host epigenetic regulation via
38 histone mimicry. *Nature 2022 610:7931.* 2022;610(7931):381-388. doi:10.1038/s41586-
39 022-05282-z
- 40 69. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long
41 COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of
42 antiplasmin. *Cardiovasc Diabetol.* Published online 2021. doi:10.1186/s12933-021-
43 01359-7

- 1 70. Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen)
2 resistant to fibrinolysis: Implications for microclot formation in COVID-19. *Biosci Rep*.
3 Published online 2021. doi:10.1042/BSR20210611
- 4 71. Ryu JK, Sozmen EG, Dixit K, et al. SARS-CoV-2 spike protein induces abnormal
5 inflammatory blood clots neutralized by fibrin immunotherapy. *bioRxiv*. Published online
6 October 13, 2021. doi:10.1101/2021.10.12.464152
- 7 72. De Michele M, d'Amati G, Leopizzi M, et al. Evidence of SARS-CoV-2 spike protein on
8 retrieved thrombi from COVID-19 patients. *J Hematol Oncol*. 2022;15(1):1-5.
9 doi:10.1186/S13045-022-01329-W/TABLES/1
- 10 73. Boribong BP, LaSalle TJ, Bartsch YC, et al. Neutrophil profiles of pediatric COVID-19 and
11 multisystem inflammatory syndrome in children. *Cell Rep Med*. 2022;3(12).
12 doi:10.1016/J.XCRM.2022.100848
- 13 74. Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of post-
14 acute COVID-19 syndrome. *Nat Commun*. 2022;13(1). doi:10.1038/S41467-021-27797-1
- 15 75. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory
16 responses in severe COVID-19 patients. *Science*. 2020;369(6504):718.
17 doi:10.1126/SCIENCE.ABC6027
- 18 76. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its
19 Relationship to Epstein-Barr Virus Reactivation. *Pathogens*. 2021;10(6).
20 doi:10.3390/PATHOGENS10060763
- 21 77. Peluso MJ, Deveau TM, Munter SE, et al. Impact of pre-existing chronic viral infection and
22 reactivation on the development of long COVID. *J Clin Invest*. Published online December
23 1, 2022. doi:10.1172/JCI163669
- 24 78. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19
25 sequelae. *Cell*. Published online 2022. doi:10.1016/j.cell.2022.01.014
- 26 79. Gu L, Deng H, Ren Z, et al. Dynamic Changes in the Microbiome and Mucosal Immune
27 Microenvironment of the Lower Respiratory Tract by Influenza Virus Infection. *Front*
28 *Microbiol*. 2019;10. doi:10.3389/FMICB.2019.02491
- 29 80. Kaul D, Rathnasinghe R, Ferres M, et al. Microbiome disturbance and resilience dynamics
30 of the upper respiratory tract during influenza A virus infection. *Nat Commun*. Published
31 online 2020. doi:10.1038/s41467-020-16429-9
- 32 81. Eastment MC, McClelland RS. Vaginal microbiota and susceptibility to HIV. *Aids*.
33 2018;32(6):687-698. doi:10.1097/QAD.0000000000001768
- 34 82. Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients
35 with post-acute COVID-19 syndrome. *Gut*. 2022;71(3):544-552. doi:10.1136/GUTJNL-
36 2021-325989
- 37 83. Giron LB, Peluso MJ, Ding J, et al. Markers of fungal translocation are elevated during
38 post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. *JCI Insight*. 2022;7(15).
39 doi:10.1172/JCI.INSIGHT.160989
- 40 84. Yonker LM, Gilboa T, Ogata AF, et al. Multisystem inflammatory syndrome in children is
41 driven by zonulin-dependent loss of gut mucosal barrier. *Journal of Clinical Investigation*.
42 Published online 2021. doi:10.1172/JCI149633
- 43 85. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of
44 intestinal tight junctions. *J Cell Sci*. Published online 2000. doi:10.1242/jcs.113.24.4435

- 1 86. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal
2 permeability, and its expression in coeliac disease. *Lancet*. Published online 2000.
3 doi:10.1016/S0140-6736(00)02169-3
- 4 87. Malik A, Tóth EN, Teng MS, et al. Distorted TCR repertoires define multisystem
5 inflammatory syndrome in children. *PLoS One*. 2022;17(10):e0274289.
6 doi:10.1371/JOURNAL.PONE.0274289
- 7 88. Kreye J, Reincke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in
8 COVID-19? *Nat Rev Immunol*. 2020;20(11):645-646. doi:10.1038/s41577-020-00458-y
- 9 89. Lanz T v., Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV
10 EBNA1 and GlialCAM. *Nature* 2022 603:7900. 2022;603(7900):321-327.
11 doi:10.1038/s41586-022-04432-7
- 12 90. McCusker RH, Kelley KW. Immune–neural connections: how the immune system’s
13 response to infectious agents influences behavior. *J Exp Biol*. 2013;216(1):84.
14 doi:10.1242/JEB.073411
- 15 91. Goehler LE, Gaykema RPA, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal
16 afferents and central autonomic pathways: early responses to intestinal infection with
17 *Campylobacter jejuni*. *Brain Behav Immun*. 2005;19(4):334-344.
18 doi:10.1016/J.BBI.2004.09.002
- 19 92. VanElzakker MB. Chronic fatigue syndrome from vagus nerve infection: A
20 psychoneuroimmunological hypothesis. *Med Hypotheses*. 2013;81(3):414-423.
21 doi:10.1016/j.mehy.2013.05.034
- 22 93. Woo MS, Shafiq M, Fitzek A, et al. Vagus nerve inflammation contributes to
23 dysautonomia in COVID-19. *medRxiv*. Published online June 20,
24 2023:2023.06.14.23291320. doi:10.1101/2023.06.14.23291320
- 25 94. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19
26 in Germany: a post-mortem case series. *Lancet Neurol*. 2020;19(11):919-929.
27 doi:10.1016/S1474-4422(20)30308-2
- 28 95. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse
29 brain. *J Exp Med*. 2021;218(3). doi:10.1084/JEM.20202135
- 30 96. Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with
31 New-Onset Alzheimer’s Disease. *J Alzheimers Dis*. 2022;89(2):411-414. doi:10.3233/JAD-
32 220717
- 33 97. Rhodes CH, Priemer DS, Karlovich E, Perl DP, Goldman J. B-Amyloid Deposits in Young
34 COVID Patients. *SSRN Electronic Journal*. Published online January 20, 2022.
35 doi:10.2139/SSRN.4003213
- 36 98. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer’s Disease-Associated Amyloid β -
37 Protein Is an Antimicrobial Peptide. *PLoS One*. 2010;5(3).
38 doi:10.1371/JOURNAL.PONE.0009505
- 39 99. Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, et al. Alzheimer’s Disease-
40 Associated β -Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain
41 Infection. *Neuron*. 2018;99(1):56. doi:10.1016/J.NEURON.2018.06.030
- 42 100. Kumar DKV, Choi HS, Washicosky KJ, et al. Amyloid- β Peptide Protects Against Microbial
43 Infection In Mouse and Worm Models of Alzheimer’s Disease. *Sci Transl Med*.
44 2016;8(340):340ra72. doi:10.1126/SCITRANSLMED.AAF1059

- 1 101. Aung A, Cui A, Maiorino L, et al. Low protease activity in B cell follicles promotes
2 retention of intact antigens after immunization. *Science (1979)*. 2023;379(6630).
3 doi:10.1126/SCIENCE.ABN8934/SUPPL_FILE/SCIENCE.ABN8934_MДАР_REPRODUCIBILIT
4 Y_CHECKLIST.PDF
- 5 102. Griffin DE. Why does viral RNA sometimes persist after recovery from acute infections?
6 *PLoS Biol*. 2022;20(6):e3001687. doi:10.1371/JOURNAL.PBIO.3001687
- 7 103. Emmler L, Felten S, Matiasek K, et al. Feline coronavirus with and without spike gene
8 mutations detected by real-time RT-PCRs in cats with feline infectious peritonitis. *J Feline*
9 *Med Surg*. 2020;22(8):791-799. doi:10.1177/1098612X19886671
- 10 104. Arshad N, Laurent-Rolle M, Ahmed WS, et al. SARS-CoV-2 accessory proteins ORF7a and
11 ORF3a use distinct mechanisms to downregulate MHC-I surface expression. *bioRxiv*.
12 Published online May 17, 2022. doi:10.1101/2022.05.17.492198
- 13 105. Moriyama M, Lucas C, Monteiro VS, Initiative YSC 2 GS, Iwasaki A. SARS-CoV-2 Omicron
14 subvariants evolved to promote further escape from MHC-I recognition. *bioRxiv*.
15 Published online December 23, 2022. doi:10.1101/2022.05.04.490614
- 16 106. Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of oral nirmatrelvir on Long COVID
17 symptoms: a case series. Published online May 5, 2022. doi:10.21203/RS.3.RS-
18 1617822/V2
- 19 107. Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. Case Report of Breakthrough Long
20 COVID and the Use of Nirmatrelvir-Ritonavir. Published online 2022.
21 doi:10.21203/rs.3.rs-1443341/v1
- 22 108. Schultz DC, Johnson RM, Ayyanathan K, et al. Pyrimidine inhibitors synergize with
23 nucleoside analogues to block SARS-CoV-2. *Nature 2022 604:7904*. 2022;604(7904):134-
24 140. doi:10.1038/s41586-022-04482-x
- 25 109. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19.
26 *medRxiv*. Published online November 5, 2022:2022.11.03.22281783.
27 doi:10.1101/2022.11.03.22281783
- 28 110. Yonker LM, Swank Z, Gilboa T, et al. Zonulin Antagonist, Larazotide (AT1001), As an
29 Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.
30 *Crit Care Explor*. 2022;4(2):e0641. doi:10.1097/CCE.0000000000000641
- 31 111. Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of
32 the human microbiome: Persistent pathogens drive chronic symptoms by interfering
33 with host metabolism, gene expression, and immunity. *Front Pediatr*. 2018;6.
34 doi:10.3389/fped.2018.00373
- 35 112. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of
36 Epstein-Barr virus associated with multiple sclerosis. *Science (1979)*. 2022;375(6578):296-
37 301.
38 doi:10.1126/SCIENCE.ABJ8222/SUPPL_FILE/SCIENCE.ABJ8222_MДАР_REPRODUCIBILITY_
39 CHECKLIST.PDF
- 40 113. Harley JB, Chen X, Pujato M, et al. Transcription factors operate across disease loci, with
41 EBNA2 implicated in autoimmunity. *Nat Genet*. 2018;50(5):699-707. doi:10.1038/s41588-
42 018-0102-3

- 1 114. Cheung CCL, Goh D, Lim X, et al. Residual SARS-CoV-2 viral antigens detected in GI and
2 hepatic tissues from five recovered patients with COVID-19. *Gut*. 2022;71(1):226-229.
3 doi:10.1136/GUTJNL-2021-324280
- 4 115. Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE. Persistent
5 alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.
6 *medRxiv*. Published online November 29, 2022. doi:10.1101/2022.11.28.22282811
- 7 116. Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of
8 SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. *Med (N Y)*. 2022;3(6):371-
9 387.e9. doi:10.1016/J.MEDJ.2022.04.001
- 10 117. Jin JC, Ananthanarayanan A, Brown JA, et al. SARS CoV-2 detected in neonatal stool
11 remote from maternal COVID-19 during pregnancy. *Pediatric Research* 2022. Published
12 online August 19, 2022:1-8. doi:10.1038/s41390-022-02266-7
- 13 118. Tejerina F, Catalan P, Rodriguez-Grande C, et al. Post-COVID-19 syndrome. SARS-CoV-2
14 RNA detection in plasma, stool, and urine in patients with persistent symptoms after
15 COVID-19. *BMC Infect Dis*. 2022;22(1):1-8. doi:10.1186/S12879-022-07153-4/FIGURES/1
- 16 119. Shedge R, Krishan K, Warriar V, Kanchan T. Postmortem Changes. *StatPearls*. Published
17 online July 25, 2022. Accessed March 29, 2023.
18 <https://www.ncbi.nlm.nih.gov/books/NBK539741/>
- 19 120. Beckford-Vera DR, Flavell RR, Seo Y, et al. First-in-human immunoPET imaging of HIV-1
20 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. *Nat Commun*.
21 2022;13(1). doi:10.1038/S41467-022-28727-5
- 22 121. Henrich TJ, Hsue PY, VanBrocklin H. Seeing Is Believing: Nuclear Imaging of HIV
23 Persistence. *Front Immunol*. 2019;10. doi:10.3389/FIMMU.2019.02077
- 24 122. Levi J, Lam T, Goth SR, et al. Imaging of Activated T Cells as an Early Predictor of Immune
25 Response to Anti-PD-1 Therapy. *Cancer Res*. 2019;79(13):3455-3465. doi:10.1158/0008-
26 5472.CAN-19-0267
- 27 123. Levi J, Duan H, Yaghoubi S, et al. Biodistribution of a Mitochondrial Metabolic Tracer,
28 [18F]F-AraG, in Healthy Volunteers. *Mol Imaging*. 2022;2022. doi:10.1155/2022/3667417
- 29 124. Ogata AF, Maley AM, Wu C, et al. Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens
30 and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with
31 Severe Disease. *Clin Chem*. 2020;66(12):1562-1572. doi:10.1093/CLINCHEM/HVAA213
- 32 125. Mohan D, Wansley DL, Sie BM, et al. PhIP-Seq characterization of serum antibodies using
33 oligonucleotide-encoded peptidomes. *Nature Protocols* 2018 13:9. 2018;13(9):1958-
34 1978. doi:10.1038/s41596-018-0025-6
- 35 126. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in
36 Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*. 2020;183(1):158-
37 168.e14. doi:10.1016/J.CELL.2020.08.017
- 38 127. McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral
39 Infection and Cancer. *Annu Rev Immunol*. 2019;37:457-495. doi:10.1146/ANNUREV-
40 IMMUNOL-041015-055318
- 41 128. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-
42 specific CD8+ T cells leads to reversible immune dysfunction. *Nat Med*.
43 2006;12(10):1198-1202. doi:10.1038/NM1482

- 1 129. Buggert M, Tauriainen J, Yamamoto T, et al. T-bet and Eomes are differentially linked to
2 the exhausted phenotype of CD8+ T cells in HIV infection. *PLoS Pathog.* 2014;10(7).
3 doi:10.1371/JOURNAL.PPAT.1004251
- 4 130. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. *Cell.* 2009;138(1):30-
5 50. doi:10.1016/J.CELL.2009.06.036
- 6 131. Kim W, Zhou JQ, Horvath SC, et al. Germinal centre-driven maturation of B cell response
7 to mRNA vaccination. *Nature.* 2022;604(7904):141-145. doi:10.1038/S41586-022-04527-
8 1
- 9 132. Bryche B, St Albin A, Murri S, et al. Massive transient damage of the olfactory epithelium
10 associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters.
11 *Brain Behav Immun.* 2020;89:579-586. doi:10.1016/J.BBI.2020.06.032
- 12 133. Chu H, Chan JFW, Yuen KY. Animal models in SARS-CoV-2 research. *Nature Methods* 2022
13 19:4. 2022;19(4):392-394. doi:10.1038/s41592-022-01447-w

14
15
16
17
18
19
20

Mechanisms by which SARS-CoV-2 reservoir may contribute to PASC

RNA and protein engage host pattern-recognition receptors to modulate the immune response and drive cytokine production and inflammation

Associated inflammation sensed by vagus nerve chemoreceptors triggers glial activation in the CNS, resulting in sickness response symptoms

Repeated recognition of persistent protein by host adaptive immune cells drives immune mediator production, exhaustion and/or altered differentiation of virus-specific T cells and B cells over time.

Antibodies created in response to SARS-CoV-2 could cross react with host proteins (molecular mimicry)

SARS-CoV-2 Reservoir




SARS-CoV-2 proteins modulate host metabolic, genetic, and epigenetic factors to drive chronic symptoms in the absence of overt inflammation or cytopathology

Associated immune dysregulation facilitates microbiome dysbiosis and/or epithelial barrier permeability

Spike or S1 protein contributes to fibrin/amyloid microclot formation or vasculature damage

Downregulation of the host immune response (including interferon signaling) facilitates the reactivation of latent pathogens such as herpesviruses

Components of SARS-CoV-2 measured in persistence studies



Diverse approaches and methodologies can be used in the study of SARS-CoV-2 reservoir

Autopsy Studies

Strengths

- Can identify SARS-CoV-2 RNA and protein in tissues that cannot be obtained safely via biopsy, including from the CNS
- Viral genome sequencing can identify SARS-CoV-2 mutations associated with persistence in certain anatomical locations
- Tissue cytopathology near identified RNA and protein can be assessed

Weaknesses

- Short postmortem interval is necessary for optimal tissue preservation
- Perimortem changes can alter the tissue's transcriptional landscape, meaning tissue is not optimized for transcriptome-based approaches that capture host immune & gene expression

Imaging Studies

Strengths

- Can identify SARS-CoV-2 spike protein and T cell activity in tissue locations in living patients that otherwise cannot be accessed via biopsy
- SARS-CoV-2 spike protein and T cell activity in a wide range of tissue sites can be measured simultaneously

Weaknesses

- High cost of analysis and imaging scanners only available in limited locations
- Radioligands are limited by penetration and specificity

Biopsy & Surgical Sample Studies

Strengths

- Samples can be preserved immediately and optimally for both genomic and protein analyses
- Allows for optimal use of sequencing technologies to characterize host immune and gene expression changes near identified SARS-CoV-2 RNA or protein (e.g., spatial transcriptomics)

Weaknesses

- Only certain tissue types can be safely obtained via biopsy, and tissue sample size must be small

Ultrasensitive Protein & Antibody Detection in Fluids

Strengths

- Analysis can be performed on body fluids (e.g., blood, saliva) which can be collected non-invasively and at routine study visits

Weaknesses

- Protein from SARS-CoV-2 reservoir in certain tissues or CNS sites may not enter body fluids or could be bound by antibodies. This could prevent recognition by relevant immunoassays
- In some cases it is known that circulating markers do not accurately reflect local responses (e.g., cytokines)

Adaptive Immune Cells as Biomarkers of Persistence

Strengths

- The adaptive immune response can act as a sensitive indicator of virus persistence, with single-molecule detection possible at the level of cognate viral epitopes displayed on the infected cell surface

Weaknesses

- Expensive and requires a large amounts of sample to isolate specific cell types

Organoid & Animal Studies

Strengths

- Can be directly infected and used to explore mechanisms of persistence, including how viral variants and mutations can contribute to the survival of infected cells

Weaknesses

- Lack of homology between animal model pathways and human pathways must be considered
- Culture and organoid models are incomplete biological systems